PD173074 (GMP)

Overview

PD173074 GMP is PD173074 ( HY-10321 ) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis . PD173074 successfully reverses FGF-2 -induced chemoresistance to enhance the effect of cisplatin ( HY-17394 ) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer .

Application

Products | Products > GMP Small Molecules | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FGFR | Products > Signaling Pathways > TGF-beta/Smad

Product Information

• Catalog No.: HY-10321G
• CAS No.: 219580-11-7
• Molecular Formula: C28H41N7O3
• Molecular Weight: 523.67
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source